Primecap Management Co. CA Invests $5.15 Million in Ingevity Corporation $NGVT

Primecap Management Co. CA bought a new position in Ingevity Corporation (NYSE:NGVT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 69,000 shares of the company’s stock, valued at approximately $5,152,000. Primecap Management Co. CA owned 0.20% of Ingevity as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC lifted its position in shares of Ingevity by 10.9% during the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the company’s stock valued at $518,000 after buying an additional 1,323 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Ingevity by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,790 shares of the company’s stock worth $863,000 after acquiring an additional 1,080 shares during the period. Empowered Funds LLC lifted its holdings in Ingevity by 12.9% during the first quarter. Empowered Funds LLC now owns 5,181 shares of the company’s stock valued at $205,000 after purchasing an additional 594 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Ingevity by 311.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock worth $23,769,000 after purchasing an additional 454,579 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Ingevity by 306.1% in the first quarter. Jane Street Group LLC now owns 88,883 shares of the company’s stock worth $3,519,000 after purchasing an additional 66,995 shares in the last quarter. Institutional investors own 91.59% of the company’s stock.

Ingevity Stock Performance

Shares of NYSE NGVT opened at $69.57 on Thursday. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61. The company has a market cap of $2.39 billion, a P/E ratio of 47.33 and a beta of 1.16. The firm’s fifty day moving average is $73.68 and its two-hundred day moving average is $71.83. Ingevity Corporation has a 52-week low of $45.85 and a 52-week high of $79.29.

Ingevity (NYSE:NGVT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. The firm had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, analysts anticipate that Ingevity Corporation will post 5.4 EPS for the current fiscal year.

Insider Buying and Selling

In other Ingevity news, CEO David H. Li sold 5,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the transaction, the chief executive officer owned 120,636 shares in the company, valued at $9,147,827.88. This trade represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of Ingevity stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total transaction of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares of the company’s stock, valued at $1,159,025.84. The trade was a 14.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 17,801 shares of company stock valued at $1,347,481 over the last quarter. Corporate insiders own 0.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on NGVT. Weiss Ratings upgraded shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Ingevity presently has a consensus rating of “Hold” and an average price target of $80.00.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.